Received: 8 May 2021
Accepted: 11 October 2021
First Online: 21 October 2021
: All experimental protocols were approved by the following 9 institutional review boards (IRB) or ethics committees (EC) with corresponding reference number, including 1) Medical Ethics Committee of Tongji Medical College of Huazhong University of Science and Technology “; 2) Clinical Trial and Biomedical Ethics Committee of West China Hospital, Sichuan University; 3) Ethics Committee of the First Affiliated Hospital of Kunming Medical University; 4) Ethics Committee of Sir Run Run Shaw Hospital, Zhejiang University School of Medicine; 5) Medical Ethics Committee of China-Japan Union Hospital of Jilin University; 6) Medical Ethics Committee of Chinese PLA General Hospital; 7) Ethics Committee of Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology; 8) Medical Science Research Ethics Committee of the First Hospital of China Medical University; 9) Medical Ethics Committee of Gansu Provincial Cancer Hospital. The IRB or/and EC for each of the nine study sites was constituted according to the requirements of the participating location. The IRB or EC was responsible for the initial and continuing review and approval of the clinical study in accordance with the requirements of the International Conference on Harmonization (ICH) Guideline for Good Clinical Practice (GCP) E6, and local regulatory requirements of each participating region. All patients gave informed consent in accordance with the protocol, the World Medical Association Declaration of Helsinki, the ICH GCP guideline, and applicable local regulatory requirements of each participating region.
: All patients gave consent to have their data published in a scientific journal.
: All authors declare no conflict of interest.